Suppr超能文献

炎症标志物作为代谢功能障碍相关脂肪性肝病的诊断和精准营养工具:来自肥胖相关性脂肪肝试验的结果。

Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial.

机构信息

Department of Nutrition, Food Sciences and Physiology and Centre for Nutrition Research, Faculty of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain.

Department of Nutrition, Food Sciences and Physiology and Centre for Nutrition Research, Faculty of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain.

出版信息

Clin Nutr. 2024 Jul;43(7):1770-1781. doi: 10.1016/j.clnu.2024.05.042. Epub 2024 May 31.

Abstract

BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing public health concern. The disease is silent, and its diagnosis is often delayed. Inflammatory markers constitute an interesting tool to act as subrogate, non-invasive markers. This study aimed to evaluate the changes of inflammatory markers throughout a two-year dietary intervention in subjects presenting MASLD, to determine which of the markers are suitable to predict the disease, and act as a customizing tool for MASLD's dietary treatment.

METHODS

Ninety-eight subjects with MASLD and forty-five controls from the Fatty Liver in Obesity (FLiO) Study were analyzed. MASLD was diagnosed and graded by ultrasound. The MASLD subjects were randomly assigned to two different dietary strategies, the American Heart Association (AHA diet) or a dietary strategy based on the Mediterranean pattern, which was specially designed for the study (FLiO diet), and then followed for two years. Hepatic status was additionally assessed through Magnetic Resonance Imaging (MRI), elastography, and determination of transaminases.

RESULTS & DISCUSSION: Inflammatory markers improved throughout the intervention in the MASLD subjects and managed to reach similar levels to controls, especially at 6 and 12 months. Additionally, leptin, adiponectin, M30, and LECT2 managed to significantly diagnose the disease at all time marks of the intervention, making them candidates for subrogate non-invasive markers of the disease. Moreover, baseline chemerin, leptin, LECT2, and M65 were used to build a predictive score to achieve greater weight loss, and therefore, which strategy could be more useful for MASLD 's treatment. The predictive score was significantly able assign a specific diet to 55% of the study participants, meaning that the remaining 45% could achieve the same amount of weight loss following either diet equally.

CONCLUSION

Inflammatory markers constitute a potential non-invasive tool to be used in MASLD screening and could also constitute an interesting tool for MASLD's treatment customization, being able to predict the effectiveness of a dietary strategy based on the initial inflammatory state of each subject.

TRIAL REGISTRATION

www.

CLINICALTRIALS

gov (NCT03183193).

摘要

背景与目的

代谢相关脂肪性肝病(MASLD)是一个日益严重的公共卫生问题。这种疾病悄无声息,诊断往往被延误。炎症标志物是一种很有前途的替代、非侵入性标志物。本研究旨在评估 MASLD 患者在两年饮食干预过程中炎症标志物的变化,以确定哪些标志物适合预测疾病,并作为 MASLD 饮食治疗的定制工具。

方法

对来自肥胖相关性脂肪肝研究(FLiO)的 98 例 MASLD 患者和 45 例对照进行分析。MASLD 通过超声诊断和分级。将 MASLD 患者随机分配到两种不同的饮食策略,即美国心脏协会(AHA 饮食)或根据地中海模式专门为该研究设计的饮食策略(FLiO 饮食),然后进行为期两年的随访。通过磁共振成像(MRI)、弹性成像和转氨酶测定进一步评估肝脏状况。

结果与讨论

MASLD 患者的炎症标志物在整个干预过程中得到改善,并设法达到与对照组相似的水平,尤其是在 6 个月和 12 个月时。此外,瘦素、脂联素、M30 和 LECT2 在整个干预过程的所有时间点都能显著诊断疾病,使它们成为疾病的替代非侵入性标志物的候选者。此外,基线 chemerin、leptin、LECT2 和 M65 用于构建预测评分以实现更大的体重减轻,因此,哪种策略对 MASLD 的治疗更有用。预测评分能够将 55%的研究参与者分配到特定的饮食方案中,这意味着剩余的 45%的参与者可以通过两种饮食方案中的任意一种达到相同的减重效果。

结论

炎症标志物是 MASLD 筛查的一种潜在非侵入性工具,也可以作为 MASLD 治疗定制的一种有趣工具,能够根据每个患者的初始炎症状态预测饮食策略的效果。

试验注册

www.clinicaltrials.gov(NCT03183193)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验